


## Four Business Areas

In October 2024, we reorganized our five existing business sectors and launched a new four-business-sector structure: Agro & Life Solutions, ICT & Mobility Solutions, Advanced Medical Solutions, and Essential & Green Materials.





## Main Products and Services generative Medicine/Cell Sales Revenue Advanced Medical CDMO\*1 Business Therapy Business (R&D) Composition Ratio 2.4% Advanced small molecule APIs\*2 CDMO Solutions Oligonucleotides\*3 CDMO Regenerative medicine/cell therapy CDMO \* The expenses related to regenerative medicine/cell therapy (R&D) will continue to be recorded as corporate shared expenses for the time being \*1 CDMO: Contract Development and Manufacturing Organization APIs: Active Pharmaceutical Ingredients APIs: Active Pharmaceutical Ingredients Nucleic acids required for cutting-edge genome-editing therapies. A typical example is gRNA exceeding 100 mer, which is much longer than typical nucleic acid drugs. The necessity of high-purity products for medical applications has been highlighted. Core Operating Income and ROIC R&D Expenses and Business Investments (cash basis) R&D Expenses Business Investments (cash basis) 4.0 12.0 6.0 -5.4 2020 2021 2022 2023 2024 (FY) CDMO business backed by advanced synthesis capabilities/ Frontrunner in the practical application of iPS cells CDMO (Small molecules and oligonucleotides) Regenerative medicine/cell therapy



Others Sumitomo Pharma (small molecule drug discovery-related), etc.

Integrated Report 2025 22

Sales Revenue

Composition Ratio

20.7%

Biorationals